Literature DB >> 16306013

Outgrowth of a transformed cell population derived from normal human BM mesenchymal stem cell culture.

Y Wang1, D L Huso, J Harrington, J Kellner, D K Jeong, J Turney, I K McNiece.   

Abstract

BACKGROUND: Human mesenchymal stem cells (hMSC) have been isolated and characterized extensively for a variety of clinical applications. Yet it is unclear how the phenomenon of hMSC plasticity can be safely and reasonably exploited for therapeutic use.
METHODS: We have generated mesenchymal stem cells (MSC) from normal human BM and identified a novel cell population with a transformed phenotype. This cell population was characterized by morphologic, immunophenotypic, cytogenetic analyzes and telomerase expression. Its tumorigenicity in NOD/SCID mice was also studied.
RESULTS: A subpopulation of cells in hMSC culture was noted to appear morphologically distinct from typical MSC. The cells were spherical, cuboidal to short spindle in shape, adherent and exhibited contact independent growth. Phenotypically the cells were CD133(+), CD34(-), CD45(-), CD90(low), CD105(-), VEGFR2(+). Cytogenetic analysis showed chromosome aneuploidy and translocations. These cells also showed a high level of telemerase activity compared with typical MSC. Upon transplantation into NOD/SCID mice, multiple macroscopic solid tumors formed in multiple organs or tissues. Histologically, these tumors were very poorly differentiated and showed aggressive growth with large areas of necrosis. DISCUSSION: The possible explanations for the origin of this cell population are: (1) the cells represent a transformed population of MSC that developed in culture; (2) abnormal cells existed in the donor BM at rare frequency and subsequently expanded in culture. In either case, the MSC culture may provide a suitable environment for transformed cells to expand or propagate in vitro. In summary, our data demonstrate the potential of transformed cells in hMSC culture and highlight the need for karyotyping as a release criteria for clinical use of MSC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16306013     DOI: 10.1080/14653240500363216

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  76 in total

Review 1.  Modeling sarcomagenesis using multipotent mesenchymal stem cells.

Authors:  Rene Rodriguez; Ruth Rubio; Pablo Menendez
Journal:  Cell Res       Date:  2011-09-20       Impact factor: 25.617

Review 2.  Stem cells and cardiac repair: a critical analysis.

Authors:  Jonathan H Dinsmore; Nabil Dib
Journal:  J Cardiovasc Transl Res       Date:  2008-01-31       Impact factor: 4.132

3.  Defining the probability that a cell therapy will produce a malignancy.

Authors:  Darwin J Prockop
Journal:  Mol Ther       Date:  2010-07       Impact factor: 11.454

4.  Sox11 is expressed in early progenitor human multipotent stromal cells and decreases with extensive expansion of the cells.

Authors:  Benjamin L Larson; Joni Ylostalo; Ryang H Lee; Carl Gregory; Darwin J Prockop
Journal:  Tissue Eng Part A       Date:  2010-07-13       Impact factor: 3.845

Review 5.  The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis.

Authors:  Jeffery J Auletta; Amelia M Bartholomew; Richard T Maziarz; Robert J Deans; Robert H Miller; Hillard M Lazarus; Jeffrey A Cohen
Journal:  Immunotherapy       Date:  2012-05       Impact factor: 4.196

6.  A shorter telomere is the key factor in preventing cultured human mesenchymal stem cells from senescence escape.

Authors:  Liu He; Yong Zheng; Yu Wan; Jian Song
Journal:  Histochem Cell Biol       Date:  2014-09       Impact factor: 4.304

7.  Genetic stability of bone marrow-derived human mesenchymal stromal cells in the Quantum System.

Authors:  Mark Jones; Marileila Varella-Garcia; Margaret Skokan; Steven Bryce; Jeffrey Schowinsky; Rebecca Peters; Boah Vang; Michelle Brecheisen; Thomas Startz; Nathan Frank; Brian Nankervis
Journal:  Cytotherapy       Date:  2013-08-28       Impact factor: 5.414

8.  Gastritis promotes an activated bone marrow-derived mesenchymal stem cell with a phenotype reminiscent of a cancer-promoting cell.

Authors:  Jessica M Donnelly; Amy C Engevik; Melinda Engevik; Michael A Schumacher; Chang Xiao; Li Yang; Roger T Worrell; Yana Zavros
Journal:  Dig Dis Sci       Date:  2013-11-08       Impact factor: 3.199

9.  Generation of mesenchymal stromal cells in the presence of platelet lysate: a phenotypic and functional comparison of umbilical cord blood- and bone marrow-derived progenitors.

Authors:  Maria Antonietta Avanzini; Maria Ester Bernardo; Angela Maria Cometa; Cesare Perotti; Nadia Zaffaroni; Francesca Novara; Livia Visai; Antonia Moretta; Claudia Del Fante; Raffaella Villa; Lynne M Ball; Willem E Fibbe; Rita Maccario; Franco Locatelli
Journal:  Haematologica       Date:  2009-09-22       Impact factor: 9.941

Review 10.  Concise review: adult multipotent stromal cells and cancer: risk or benefit?

Authors:  Gwendal Lazennec; Christian Jorgensen
Journal:  Stem Cells       Date:  2008-04-03       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.